Literature DB >> 34344394

Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives.

Xianmin Dai1, Jiayi Feng1, Yi Chen1, Si Huang1, Xiaofei Shi1, Xia Liu2, Yang Sun3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the world's largest chronic liver disease, while there is still no specific drug to treat NAFLD. Traditional Chinese Medicine (TCM) have been widely used in hepatic diseases for centuries in Asia, and TCM's holistic concept and differentiation treatment of NAFLD show their advantages in the treatment of this complex metabolic disease. However, the multi-compounds and multi-targets are big obstacle for the study of TCM. Here, we summarize the pharmacological actions of active ingredients from frequently used single herbs in TCM compounds. The combined mechanism of herbs in TCM compounds are further discussed to explore their comprehensive effects on NAFLD. This article aims to summarize multiple functions and find the common ground for TCM treatment on NAFLD, thus providing enrichment to the scientific connotation of TCM theories and promotes the exploration of TCM therapies on NAFLD.
© 2021. The Author(s).

Entities:  

Keywords:  Mechanism; NAFLD; Single herb; TCM; TCM compound

Year:  2021        PMID: 34344394     DOI: 10.1186/s13020-021-00469-4

Source DB:  PubMed          Journal:  Chin Med        ISSN: 1749-8546            Impact factor:   5.455


  105 in total

1.  Steatohepatitis: a tale of two "hits"?

Authors:  C P Day; O F James
Journal:  Gastroenterology       Date:  1998-04       Impact factor: 22.682

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 3.  A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

Authors:  Mohammed Eslam; Philip N Newsome; Shiv K Sarin; Quentin M Anstee; Giovanni Targher; Manuel Romero-Gomez; Shira Zelber-Sagi; Vincent Wai-Sun Wong; Jean-François Dufour; Jörn M Schattenberg; Takumi Kawaguchi; Marco Arrese; Luca Valenti; Gamal Shiha; Claudio Tiribelli; Hannele Yki-Järvinen; Jian-Gao Fan; Henning Grønbæk; Yusuf Yilmaz; Helena Cortez-Pinto; Claudia P Oliveira; Pierre Bedossa; Leon A Adams; Ming-Hua Zheng; Yasser Fouad; Wah-Kheong Chan; Nahum Mendez-Sanchez; Sang Hoon Ahn; Laurent Castera; Elisabetta Bugianesi; Vlad Ratziu; Jacob George
Journal:  J Hepatol       Date:  2020-04-08       Impact factor: 25.083

Review 4.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.

Authors:  Anna M Diehl; Christopher Day
Journal:  N Engl J Med       Date:  2017-11-23       Impact factor: 91.245

Review 5.  MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Authors:  Mohammed Eslam; Arun J Sanyal; Jacob George
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

6.  From NAFLD to MAFLD: when pathophysiology succeeds.

Authors:  Herbert Tilg; Maria Effenberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-27       Impact factor: 46.802

7.  Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.

Authors:  Donghee Kim; Andrew A Li; Chiranjeevi Gadiparthi; Muhammad Ali Khan; George Cholankeril; Jeffrey S Glenn; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2018-09-01       Impact factor: 22.682

Review 8.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine.

Authors:  Tingting Shi; Li Wu; Wenjun Ma; Liping Ju; Minghui Bai; Xiaowei Chen; Shourong Liu; Xingxin Yang; Junping Shi
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-04       Impact factor: 2.629

Review 9.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.

Authors:  Timothy Hardy; Fiona Oakley; Quentin M Anstee; Christopher P Day
Journal:  Annu Rev Pathol       Date:  2016-03-03       Impact factor: 23.472

Review 10.  Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".

Authors:  Yan-Lan Fang; Hong Chen; Chun-Lin Wang; Li Liang
Journal:  World J Gastroenterol       Date:  2018-07-21       Impact factor: 5.742

View more
  8 in total

1.  Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification.

Authors:  Hui Jiang; Tangyou Mao; Yuyue Liu; Xiang Tan; Zhongmei Sun; Yuan Cheng; Xiao Han; Yang Zhang; Jiali Wang; Lei Shi; Yi Guo; Junxiang Li; Haixiao Han
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction.

Authors:  Yuhan Cao; Jingying Shi; Luyao Song; Junjiu Xu; Henglei Lu; Jianhua Sun; Jinjun Hou; Jing Chen; Wanying Wu; Likun Gong
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

3.  Honokiol attenuates lipotoxicity in hepatocytes via activating SIRT3-AMPK mediated lipophagy.

Authors:  Jingxin Liu; Tian Zhang; Jianzhong Zhu; Shuangchen Ruan; Rongsong Li; Bing Guo; Ligen Lin
Journal:  Chin Med       Date:  2021-11-10       Impact factor: 5.455

Review 4.  Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine.

Authors:  Mingmei Shao; Yifei Lu; Hongjiao Xiang; Junmin Wang; Guang Ji; Tao Wu
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

5.  Exploring the Protective Effects and Mechanism of Huaji Jianpi Decoction against Nonalcoholic Fatty Liver Disease by Network Pharmacology and Experimental Validation.

Authors:  Hongkun Xue; Yu Wang; Hongwei Xiang; Qi Song; Guowei Zhang; Jianguo Wang; Shaoqin Ge
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-26       Impact factor: 2.650

Review 6.  Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.

Authors:  Xiang Chen; Menghan Liu; Jun Tang; Ning Wang; Yibin Feng; Haotian Ma
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

Review 7.  Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.

Authors:  Zhijia Zhou; Jinghao Zhang; Liping You; Tao Wang; Kaixia Wang; Lingtai Wang; Xiaoni Kong; Yueqiu Gao; Xuehua Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

8.  Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.

Authors:  Zheng Xu; Fan-Wei Wu; Xuan Niu; Xiao-Peng Lu; Yan-Rong Li; Shu-Ting Zhang; Jun-Zhao Ou; Xue-Mei Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.